EC Number   |
Inhibitors |
Structure |
|---|
   3.4.11.20 | (2S,17S,20S,21R)-21-amino-5-(4-benzoylbenzyl)-2-[4-(hex-5-ynoylamino)butyl]-20-hydroxy-17-(naphthalen-2-ylmethyl)-4,7,16,19-tetraoxo-22-phenyl-9,12-dioxa-3,6,15,18-tetraazadocosan-1-amide |
- |
   |
| 3.4.11.20 | 1,10-phenanthroline |
complete inhibition at 2 mM |
|
| 3.4.11.20 | 1,10-phenanthroline |
treatment with 1,10-ortho-phenanthroline in order to deplete metal ions, results in a residual activity of about 8% compared to the initial activity. Activity is partially restored by the addition of divalent metal cations with Zn2+ being the most potent |
|
| 3.4.11.20 | 1,10-phenanthroline |
1 mM, 80% inhibition |
|
| 3.4.11.20 | 1,10-phenanthroline |
- |
|
| 3.4.11.20 | 1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (4-phenyl-butyl)-amide |
- |
|
| 3.4.11.20 | 1-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid 4-fluoro-benzylamide |
- |
|
| 3.4.11.20 | 2-(4-benzyl-piperidine-1-carbonyl)-4-methyl-pentanoic acid hydroxyamide |
- |
|
| 3.4.11.20 | 2-benzyl-3-(3,4-dihydro-1H-isoquinolin-2-yl)-N-hydroxy-3-oxo-propionamide |
- |
|
| 3.4.11.20 | 2-benzyl-3-(4-benzyl-piperazin-1-yl)-N-hydroxy-3-oxo-propionamide |
- |
|
